CUTTING EDGE INNOVATION TO FIND
A BETTER TOMORROW
R&D Centres
Over the years, Glenmark has built the resources and talent to work on solving serious medical problems, while doing the right thing for patients, people and communities across the world.
Glenmark’s R&D centres are dedicated to address unmet medical needs in especially in the therapy areas based on their significant size, rapid rates of growth, and our cumulative experience and track record in patient-focused innovation.
Research and development (R&D) Centers
Sinnar
Glenmark established its first R&D center in Sinnar, Maharashtra, India. It focuses on formulations development and analytical research of specialty and branded formulations for the global markets. The research is based on dosage forms for therapeutic areas like respiratory, dermatology, oncology, cardiovascular, anti-diabetes, etc., and facilitates research of aerosols of various indications (metered dose inhalers, dry powder inhalers, nebulizers and nasal sprays) through some of the best experimental apparatus in the country.
Taloja
The Glenmark R&D center in Taloja, Mumbai, India, is focused on identifying filing opportunities by doing effective product selection and patent landscaping. The R&D unit works in co-ordination with the Intellectual Property Management team to develop cost effective and patent-driven generic formulations. The center is equipped for research on a variety of dosage forms such as oral solids, semi-solids, parenteral (complex injectable and liposomal products) and aerosols for various indications.
Mahape
The R&D center in Mahape, Mumbai, India, has end-to-end capabilities for discovery and development of small molecule entities from target selection to clinical development. The research facility is equipped with modern infrastructure required to carry out research activities like process and analytical chemistry, bulk actives, discovery, in-vitro and in-vivo, tissue culture, toxicology, antibody, pharmacokinetics supported by project management, clinical, regulatory affairs and Intellectual Property Management.
